Just as how every week we hear about another revolutionary, groundbreaking discovery in cancer research, this article below says that the problem is widespread in all medical research. It’s gotten so bad that medical committees are actually admonishing scientists for hyping up their mundane research results. Every minor item is inflated into a Nobel Prize-worthy breakthrough. It’s really bad if research overseers and administrators are taking note.
In addition to inflating claims for what researched treatments can do, researchers are also minimizing the coverage on negative results from tests and studies. It’s like everybody wants to be a top researcher even if their results are mundane, or even negative. Everything is being spun into a big deal. And scientists have been known to alter hypotheses to better fit theories and models, after the experiments have been done.
One thing they don’t cover in this article is the Big Pharma focus on the ‘drugs’ that can treat disease. There is no research being done on anything outside of a drug that can be patented. And much of the ‘research’ that is done on natural compounds is just to identify the most active ingredient so they can isolate it, patent it and then turn it into a profitable drug. No consideration that ‘the whole plant may be greater than the sum of its parts’ because they must profit off of it. This is just a shortcoming of the business of drugs. If it’s bad for profits, it’s going to be suppressed even though it may be good for people. And that’s the big problem with Big Pharma and the ‘profits are the number one priority’ paradigm. The very business model dictates that they can’t look for, find, or allow anyone else to massively publicize any cheap, readily available, effective treatment or cure for any disease that’s profitable to treat endlessly.
Would you read a story if this was the headline: “New study raises questions about an experimental treatment that might not work and won’t be ready for a long time.”
What gets clicks? Words like “breakthrough,” “groundbreaking,” “game changer” and “lifesaver.” And that’s how much of medical news is described.
In one week last June, researchers counted 36 different cancer drugs being described using those superlatives.
But when they took a closer look at the actual drugs, half were not yet approved as safe and effective, and some hadn’t even been tried on humans.
PR machine feeds the hype
So, who’s hyping the science? Everybody, it turns out.
Seeds of hype have been found in many of the press releases sent out by universities and research organizations.
And there’s evidence of that hype being routinely amplified by reporters, scientists and scientific journals.
This hyper-optimism has been measured by examining the words scientists use when they write their research papers. Since the 1970s, the use of positive words in scientific abstracts increased by 880 per cent, according to a study last December in the British Medical Journal.
And now, the world’s stem cell scientists have been told to stop the hype.
The ISSCR represents more than 4,000 scientists in 60 countries, all investigating the promise of stem cells, which have the potential to develop into any tissue in the body.
In their updated guidelines on the research and development of stem cell therapies, they’ve created a special section about communication that advises researchers to stop exaggerating, oversimplifying and overpromising how soon patients will benefit from their research.
Because people are getting hurt.
Last December, the Food and Drug Administration in the U.S. issued a warning letter to a U.S.-based company offering stem cell therapies for a range of diseases, including autism, multiple sclerosis and Parkinson’s disease. And a U.K. newspaper claims its undercover investigation lead to the closure of a controversial clinic in Germany where a child died after having stem cells injected into his brain.
“We recognize that there is essentially an industry already out there that is marketing unproven therapies directly to patients,” said George Daley, a member of the ISSCR and a professor at Harvard Medical School.
“It is part of the concern that has raised the alarm and part of the impetus behind having these guidelines.”
Read The 5th Wave, now a major motion picture! Only $5.99 in hardcover!
Downplaying negative findings
To help the public better understand the uncertainties and risks inherent in stem cell science, the ISSCR is calling on its scientists to do a better job of managing expectations.
The guidelines warn that some study findings are being “spun” by scientists who “change the goalposts” when their findings fall short, downplaying their original research targets when they don’t achieve statistical significance and highlighting secondary outcomes that do meet the statistical threshold.
Another problem? Overly optimistic predictions that stem cell treatments are just around the corner.
One recent study showed that when media report timelines, they usually predict a drug will be ready for patients within five to 10 years, or even sooner.
“We may be afraid to break the bad news that many studies do not result in statistically significant or clinically meaningful effects,” the BMJ authors wrote.
That can lead to the “file drawer” effect, where negative results end up being tossed aside and never published, even though it can be just as important to know what doesn’t work.
And there’s evidence that a publication bias has emerged that is distorting the scientific record because only the positive results are ending up in print.
Publish all results — not just the positive
That has prompted a campaign to liberate the lost data, with scientists demanding that all clinical trials be published and all data be made available.
In the new guidelines, the ISSCR advises its researchers to promptly publish “results regardless of whether they are positive, negative or inconclusive.”
And if the results look promising, the guidelines warn, scientists should keep any predictions about future benefits accurate, circumspect and restrained.
“No doubt, the path forward will be fraught with setbacks, and not all of the clinical trials will work,” said ISSCR president Sean Morrison.
But the scientists are not discouraged by the realities of their world.